- Home
- SGLY vs CNSP Comparison
SGLY vs CNSP Comparison
Compare SGLY & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SGLY | CNSP |
|---|---|---|
| Founded | 2001 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 8.5M |
| IPO Year | 2008 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SGLY | CNSP |
|---|---|---|
| Price | $0.43 | $3.99 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.2M | 16.7K |
| Earning Date | 11-24-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.03 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,693,264.00 | N/A |
| Revenue This Year | $2,964.44 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.23 | $1.90 |
| 52 Week High | $8.65 | $10.54 |
Technical Indicators
Market Signals| Indicator | SGLY | CNSP |
|---|---|---|
| Relative Strength Index (RSI) | 40.00 | 33.57 |
| Support Level | $0.27 | $2.01 |
| Resistance Level | $0.59 | $4.00 |
| Average True Range (ATR) | 0.10 | 0.66 |
| MACD | 0.05 | -0.09 |
| Stochastic Oscillator | 51.27 | 5.62 |
Price Performance
Historical ComparisonAbout SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.